Serclutamab talirine

托思诺妥单抗

Report date: 2026/04/14 20:00:15

Base Information

Drug NameSerclutamab talirine
Drug Alias NameABBV-321
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SGD-1882 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agentsEpidermal growth factor receptor erbB1 antagonists
TargetsDNAEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaIsrael
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A